Clinical kidney journal · 2024
Albuminuria after induction treatment and kidney prognosis in ANCA-associated glomerulonephritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chalkia Aglaia, Jones Rachel, Smith Rona, Willcocks Lisa, Jayne David
Аннотация
INTRODUCTION: It remains unclear whether persisting proteinuria in ANCA-associated glomerulonephritis (AAGN) reflects damage from the initial injury or ongoing inflammation.
METHODS: A retrospective, single-centre study of biopsy-proven AAGN was performed. The study defined the 'albuminuria' group as urine albumin-to-creatinine ratio (ACR) >300 mg/g and the 'no albuminuria' group as ACR ≤300 mg/g at 6 months. We sought the clinical and histopathological characteristics of both the initial and subsequent biopsies and long-term kidney outcomes stratified by albuminuria levels.
RESULTS: Two hundred and eighteen patients were included. Within the first 6 months, 28 (13%) died or progressed to end-stage kidney disease (ESKD). Among the remaining 190 patients, 37% had an ACR >300 mg/g at 6 months. The albuminuria group more frequently presented with a Berden mixed or crescentic class and had higher glomerular activity on the initial biopsy. They were more often male (OR 2.75; 95% CI 1.15-6.54), younger age (OR 0.96; 95% CI 0.93-0.99), and had fewer normal glomeruli in the biopsy (OR 0.96; 95% CI 0.93-0.99) compared with the group without albuminuria. Over the initial 5-year period, the recovery in eGFR was lower in the albuminuria group (adjusted mean difference in ΔeGFR -12.5 mL/min per 1.73 m2; 95% CI -15.8 to -9.1). In multivariable analysis, ACR >300 mg/g was associated with a higher risk of ESKD, even after adjusting for Berden classification and eGFR at diagnosis (hazard ratio 6.53; 95% CI 1.49-28.50).
CONCLUSIONS: In a well-defined cohort of AAGN, one-third of the patients, primarily younger males with a lower percentage of normal glomeruli, had persisting albuminuria after induction treatment which was associated with worse kidney outcomes independent of Berden class and eGFR at diagnosis.
METHODS: A retrospective, single-centre study of biopsy-proven AAGN was performed. The study defined the 'albuminuria' group as urine albumin-to-creatinine ratio (ACR) >300 mg/g and the 'no albuminuria' group as ACR ≤300 mg/g at 6 months. We sought the clinical and histopathological characteristics of both the initial and subsequent biopsies and long-term kidney outcomes stratified by albuminuria levels.
RESULTS: Two hundred and eighteen patients were included. Within the first 6 months, 28 (13%) died or progressed to end-stage kidney disease (ESKD). Among the remaining 190 patients, 37% had an ACR >300 mg/g at 6 months. The albuminuria group more frequently presented with a Berden mixed or crescentic class and had higher glomerular activity on the initial biopsy. They were more often male (OR 2.75; 95% CI 1.15-6.54), younger age (OR 0.96; 95% CI 0.93-0.99), and had fewer normal glomeruli in the biopsy (OR 0.96; 95% CI 0.93-0.99) compared with the group without albuminuria. Over the initial 5-year period, the recovery in eGFR was lower in the albuminuria group (adjusted mean difference in ΔeGFR -12.5 mL/min per 1.73 m2; 95% CI -15.8 to -9.1). In multivariable analysis, ACR >300 mg/g was associated with a higher risk of ESKD, even after adjusting for Berden classification and eGFR at diagnosis (hazard ratio 6.53; 95% CI 1.49-28.50).
CONCLUSIONS: In a well-defined cohort of AAGN, one-third of the patients, primarily younger males with a lower percentage of normal glomeruli, had persisting albuminuria after induction treatment which was associated with worse kidney outcomes independent of Berden class and eGFR at diagnosis.